The National AIDS Treatment Advocacy Project - NATAP - provides the latest in HIV and AIDS drug research and treatment information as well as comprehensive reports and developments from the Fifth Retroviruses and Opportunistic Infections conference, as well as from the ICAR, ICAAC, IDSA, European and International HIV and AIDS conferences, and from other sources. 

REPORTS FROM IDSA and ICAAC CONFERENCES, THE FDA, and OTHER SOURCES

• IDSA Conference Highlights (11/15/97) (Infectious Disease Society of America)

• 1st Report of Highlights From ICAAC (10/10/97)

• Laboratories That Offer the Ultra-senstive PCR Test to Individuals (9/25/97)

• Report of Day 2 From FDA ADAC Hearing: on Using Viral Load as an Endpoint in Studies (8/28/97)

• Report From FDA Hearing on Using Viral Load as an Endpoint (7/18/97)

• FDA Proposal for Using Viral Load in Clinical Studies (5/25/97)

• 10th International Conference on Antiviral Research (5/25/97)

pdf

Post 4th Retroviruses Conference Reports

• ACTG 316 Perspectives on Vertical Transmission (10/11/97)

• Virus Activity in the Lymph Tissue; Reservoirs of virus (9/30/97)

• Induction/Maintenance: Hydroxyurea/ddI Therapy in Early Disease (8/25/97)

• Laboratories That Offer the Ultra-senstive PCR Test to Individuals (9/25/97)

• 800 Telephone Number Announced for 3 1592U89 Compassionate Use Programs (8/8/97)

• 1592U89: Cross-Resistance With Nucleosides and Expanded Access and CNS Penetration in Animal Models (7/29/97)

• FDA Receives Reports of 83 Cases of Diabetes Like Symptoms for Individuals Taking Protease Inhibitors (6/18/97)

• FDA Proposal: Using Viral Load in AIDS Clinical Trials (5/25/97)

• Report of Day 2 From FDA: ADAC Hearing on Using Viral Load as an Endpoint in Studies (8/28/97)

• First Oral PMPA Study Starts (5/8/97)

• Bis-Pom PMEA (5/3/97)

• PMPA: first human data (5/3/97)

• 10th International Conference on Antiviral Research (ICAR) (5/3/97)

• Glaxo Wellcome announces 1592U89 Compassionate Use Program

• d4T + ddI -- for treatment-naive (modified 5/3/97)

• Merck Study 028 Stopped: Preliminary Data (4/23/97)

• Nucleoside Resistance and Cross-Resistance (4/12/97)

• Mutations in HIV-1 protease associated with drug resistance (modified 5/9/97)

• Nelfinavir (modified 4/29/97) general information, study results (CD4 and viral load), dosing schedule, eating instructions, drug interactions, combination with other protease inhibitors and NNRTIs, side effects, resistance, cross-resistance

• d4T+ ddI for Individuals with Prior Treatment-Experience (added 3/24/97)

pdf

• Viracept Approved for Adults and Children and Ritonavir Approved for Children (added 3/24/97)

pdf

• Hydroxyurea with ddI or ddI/d4T: a novel approach to HIV therapy (added 3/14/97)

• Ritonavir + Saquinavir: 24 week data (3/11/97)

• Altis I & II: a pilot open label study of d4T/3TC in treatment-naive and experienced individuals (3/9/97)

• MKC-442 (3/9/97)

pdf

• 1592 expanded access announcement (3/5/97)

pdf

• The Duration of Viral Suppression is predicted by Viral Load During Protease Therapy (2/27/97)

• ACTG 320 stopped due to convincing data demonstrating clinical superiority (2/27/97)

• DMP-266: an NNRTI; early safety and efficacy data (modified 1/31/97)

POST BIRMINGHAM CONFERENCE REPORTS

• 141W94 double protease inhibitor study & brief protease therapy discussion (1/15/97)

• Access programs to viral load testing from Chiron and Roche (1/15/97)

• Ritonavir plus AZT plus ddC (1/8/97)

• Ritonavir plus AZT plus 3TC (1/8/97)

• Ritonavir plus saquinavir (1/8/97)